- Home
- PBT vs ABUS Comparison
PBT vs ABUS Comparison
Compare PBT & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- ABUS
- Stock Information
- Founded
- PBT 1980
- ABUS 2005
- Country
- PBT United States
- ABUS United States
- Employees
- PBT N/A
- ABUS N/A
- Industry
- PBT Oil & Gas Production
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- ABUS Health Care
- Exchange
- PBT Nasdaq
- ABUS Nasdaq
- Market Cap
- PBT 562.6M
- ABUS 611.0M
- IPO Year
- PBT N/A
- ABUS N/A
- Fundamental
- Price
- PBT $15.83
- ABUS $3.37
- Analyst Decision
- PBT
- ABUS Strong Buy
- Analyst Count
- PBT 0
- ABUS 3
- Target Price
- PBT N/A
- ABUS $5.67
- AVG Volume (30 Days)
- PBT 159.3K
- ABUS 636.5K
- Earning Date
- PBT 01-01-0001
- ABUS 08-06-2025
- Dividend Yield
- PBT 3.37%
- ABUS N/A
- EPS Growth
- PBT N/A
- ABUS N/A
- EPS
- PBT 0.48
- ABUS N/A
- Revenue
- PBT $24,140,674.00
- ABUS $15,416,000.00
- Revenue This Year
- PBT N/A
- ABUS $3.35
- Revenue Next Year
- PBT N/A
- ABUS N/A
- P/E Ratio
- PBT $32.74
- ABUS N/A
- Revenue Growth
- PBT N/A
- ABUS 53.23
- 52 Week Low
- PBT $8.01
- ABUS $2.71
- 52 Week High
- PBT $16.65
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- PBT 73.50
- ABUS 54.05
- Support Level
- PBT $15.43
- ABUS $3.33
- Resistance Level
- PBT $13.70
- ABUS $3.45
- Average True Range (ATR)
- PBT 0.68
- ABUS 0.12
- MACD
- PBT 0.12
- ABUS 0.01
- Stochastic Oscillator
- PBT 77.84
- ABUS 36.21
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.